Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (5)
  • Open Access

    ARTICLE

    HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation

    YUEZHOU ZHANG1,#, ZHAO ZHANG2,#, JINXIN DONG1, CHANGAN LIU1,*

    Oncology Research, Vol.33, No.1, pp. 83-102, 2025, DOI:10.32604/or.2024.055866 - 20 December 2024

    Abstract Background: Aberrant expression of RNA-binding proteins (RBPs) has been linked to a variety of diseases, including hematological disorders, cardiovascular diseases, and multiple types of cancer. Heterogeneous nuclear ribonucleoprotein C (HNRNPC), a member belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family, plays a pivotal role in nucleic acid metabolism. Previous studies have underscored the significance of HNRNPC in tumorigenesis; however, its specific role in malignant tumor progression remains inadequately characterized. Methods: We leveraged publicly available databases, including The Cancer Genome Atlas (TCGA), to explore the potential involvement of HNRNPC across various cancers. Additionally, we performed experimental… More > Graphic Abstract

    HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation

  • Open Access

    ARTICLE

    Pan-cancer analysis of RNA 5-methylcytosine reader (ALYREF)

    XING YE1,#, ZHOUTING TUO2,#, KAI CHEN3, RUICHENG WU3, JIE WANG3, QINGXIN YU4, LUXIA YE5, AKIRA MIYAMOTO6, KOO HAN YOO7, CHI ZHANG8, WURAN WEI3, DENGXIONG LI3,*, DECHAO FENG3,*

    Oncology Research, Vol.32, No.3, pp. 503-515, 2024, DOI:10.32604/or.2024.045050 - 06 February 2024

    Abstract The increasing interest in RNA modifications has significantly advanced epigenomic and epitranscriptomic technologies. This study focuses on the immuno-oncological impact of ALYREF in human cancer through a pan-cancer analysis, enhancing understanding of this gene’s role in cancer. We observed differential ALYREF expression between tumor and normal samples, correlating strongly with prognosis in various cancers, particularly kidney renal papillary cell carcinoma (KIRP) and liver hepatocellular carcinoma (LIHC). ALYREF showed a negative correlation with most tumor-infiltrating cells in lung squamous cell carcinoma (LUSC) and lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), while positive correlations were noted in More >

  • Open Access

    ARTICLE

    A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker

    YANGQING HUANG1,2, XINLAN ZHOU1, XIUFEN LI1, DAN HUANG1, ZHONG FANG3,*, RONGRONG DING1,*

    Oncology Research, Vol.31, No.2, pp. 193-205, 2023, DOI:10.32604/or.2023.027112 - 10 April 2023

    Abstract Sterol o-acyltransferase1 (SOAT1) is an enzyme that regulates lipid metabolism. Nevertheless, the predictive value of SOAT1 regarding immune responses in cancer is not fully understood. Herein, we aimed to expound the predictive value and the potential biological functions of SOAT1 in pan-cancer. Raw data related to SOAT1 expression in 33 different types of cancer were acquired from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. SOAT1 expression was significantly increased in most cancers and showed a distinct correlation with prognosis. This enhanced expression of the SOAT1 gene was confirmed by evaluating SOAT1 protein More >

  • Open Access

    ARTICLE

    A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

    XIANGLAI JIANG1,2,3,4,#, JIN HE2,#, YONGFENG WANG2,3,4,5,#, JIAHUI LIU5, XIANGYANG LI5, XIANGUI HE5, HUI CAI2,3,4,*

    BIOCELL, Vol.47, No.2, pp. 351-366, 2023, DOI:10.32604/biocell.2023.025157 - 18 November 2022

    Abstract B and T-lymphocyte attenuator (BTLA) plays an immunosuppressive role by inhibiting T- and B-cell functions. BTLA is associated with a variety of diseases, especially cancer immunity. However, the function of BTLA in various cancers and its clinical prognostic value have still not been comprehensively analyzed. This study aimed to identify the relationship between BTLA and cancer from the perspectives of differences in BTLA expression, its clinical value, immune infiltration, and the correlation with immune-related genes in various cancers. Data regarding mRNA expression, miRNA expression, lncRNA expression, and clinical data of patients of 33 existing cancers… More >

  • Open Access

    ARTICLE

    Comprehensive analysis of the expression and prognosis for APOE in malignancies: A pan-cancer analysis

    SHOUKAI YU1,2,3,*, LINGMEI QIAN1, JUN MA1,*

    Oncology Research, Vol.30, No.1, pp. 13-22, 2022, DOI:10.32604/or.2022.026141 - 06 December 2022

    Abstract Apolipoprotein E (APOE), a gene identified as one of the strongest genetic factors contributing to the risk determinant of developing late-onset Alzheimer’s disease (AD), may also contribute to the risk of cancer. However, no pan-cancer analysis has been conducted specifically for the APOE gene. In this study, we investigated the oncogenic role of the APOE gene across cancers by GEO (Gene Expression Omnibus) and TCGA (The Cancer Genome Atlas). Based on the available data, we found that most cancer types overexpress APOE, and clear associations exist between the expression level of APOE and prognosis in tumor patients. The… More >

Displaying 1-10 on page 1 of 5. Per Page